August 8, 2005 8:25 AM PDT
Tata moves into medical research
- Related Stories
-
Tata unit expands its global network
July 1, 2005 -
India's renaissance: U.S.-style labor pains
June 28, 2005 -
India's renaissance: Move over, China
June 27, 2005 -
India's TCS on a hiring spree
June 22, 2005
The Life Sciences Organization, a new group within
"They did the biological reasoning to determine that the protein is related to the aging process. Our task is to determine several molecules that could suppress the activity of the protein,"
If Tata can come up with a viable molecule, Congenia will then subsequently conduct the animal and human studies in Tata's facilities.
The life sciences group remains somewhat experimental. Tata hasn't fully worked out all of the aspects of the business model, Vidyasagar said, and the group will not take on additional clients until after the Congenia deal, which is expected to last 18 months.
Still, Vidyasagar said that conceivably, molecular outsourcing could cut the time it takes to deliver a new drug to market by 10 percent and reduce costs by close to 50 percent for a company developing a new drug. Life sciences start-ups with this sort of arrangement could then spend more time discovering new proteins.
The move into drug development is part of an ambitious growth plans of Mumbai-based Tata. The company wants to be one of the top 10 IT service providers worldwide (it's currently around 14th) and
Like IBM and other large software companies, Tata has created and marketed software for the health care and drug industries. In June, the company released Bio-Suite, a set of tools for bioinformatics. Tata also provides support services for pharmaceutical companies.
Developing molecules for medicine, however, represents a completely new discipline. "You can say that again," Vidyasagar said. "But our CEO has been very supportive."
To this end, about four years ago Vidyasagar began to recruit chemists and other pharmaceutical specialists.
Tata will also outsource some of the work on the Congenia contract. Some of the wet chemistry and crystallography work will be carried out by a subcontractor called Altiora Ventures in Israel.
Over time, if its life sciences group succeeds, Tata could also possibly expand from simply conducting research in IT and chemistry to actually discovering proteins.
"It is not out of the question," Vidyasagar said.
See more CNET content tagged:
Tata Consultancy Services Ltd.,
protein,
molecule,
life science,
medical research
Meanwhile in news of the world, India and Italy have cured cancer and the common cold, but will not be exporting the cures to the USA because of "bad science" sez the FDA.
- Mohan, Author: http://www.offshoringmanagement.com